TrialSignal
Clinical trial intelligence report
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00707304
Status
COMPLETED
Phase
Phase 3
Sponsor
Agennix
Executive brief
Investment-Ready Snapshot
The FORTIS-M trial evaluated the safety and efficacy of talactoferrin in patients with non-small cell lung cancer (NSCLC) who had failed two or more prior treatment regimens. The study aimed to determine if talactoferrin could improve overall survival when combined with best supportive care.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00707304
Indication
Non Small Cell Lung Cancer
Modality
small molecule
Target
Non-small Cell Lung Cancer
Intervention
Talactoferrin, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.